TABLE 5.
Characteristics of patients who have received commercial CAR‐T cells in the real world [Correction added on August 27, 2021, after first online publication: In the heading of Table 5, the horizontal bars under Axicabtagene ciloleucel and Tisagenlecleucel were corrected in this version.]
| Axicabtagene ciloleucel | Tisagenlecleucel | ||||
|---|---|---|---|---|---|
| Nastoupil et al. 44 (N = 298) | Pasquini et al. 46 CIBMTR (N = 533) | Riedell et al. 20 (N = 158) | Riedell et al. 20 (N = 86) | Pasquini et al. 47 CIBMTR (N = 155) | |
| Histology, % | |||||
| DLBCL | 68 | – | 87 | 95 | – |
| tFL | 26 | 30 | – | – | 27 |
| PMBCL | 6 | – | – | – | – |
| Other | 0 | – | 13 | 5 | – |
| Median age, years (range) | 60 (21–83) | 61 (19–86) | 59 (18–85) | 67 (29–88) | 65 (18–89) |
| Patients ≥65 years, % | 52 a | 37 | 34 | 62 | 53 |
| HGBCL/double/triple hit, % | 23 b | 36 | – | – | 11 |
| Refractory/resistant to last line of therapy, % | 42 | 62 | 55 | 82 | – |
| ECOG PS, % | |||||
| 0–1 | 80 | 80 | 90 | 95 | 83 |
| 2+ | 19 | 4 | – | – | 5 |
| Previous autoSCT, % | 33 | 32 | 27 | 26 | 26 |
| Previous lines of therapy, median (range) | 3 (2–11) | – | 3 (2–10) | 4 (2–9) | 4 (0–11) |
| ≥3, % | 75 | 66 c | 73 | 86 | – |
| Received bridging therapy, % | 53 d | – | 61 | 75 | – |
| Patients who underwent leukapheresis, n | 298 | – | 170 | 94 | – |
| Patients who received CAR‐T cells, n (%) | 275 (92) | 750 | 158 (93) | 86 (91) | 155 |
Note: The purpose of this table is to summarize data. Head‐to‐head studies have not been performed and no comparisons can be made.
Abbreviations: autoSCT, autologous stem cell transplant; CAR, chimeric antigen receptor; CIBMTR, Center for International Blood and Marrow Transplant Research; DLBCL, diffuse large B‐cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; HGBCL, high‐grade B‐cell lymphoma; PMBCL, primary mediastinal B‐cell lymphoma; tFL, transformed follicular lymphoma.
‐ refers to not reported or known values.
Patients ≥60 years.
Double/triple hit.
>3 prior lines of therapy.
Bridging therapies included chemotherapy (54%), steroids only (23%), radiation therapy (12%), and targeted regimens (10%).